Inpatient venous thromboembolism (VTE) is a priority preventable illness; risk in cancer
varies and prophylaxis is inconsistently used. A previously validated tool (Khorana …

Essentials• The Khorana score is validated for risk of venous thromboembolism (VTE) in
cancer outpatients.• We conducted a multicenter analysis of medically hospitalized cancer …

Cancer and its treatment are recognized risk factors for VTE. Compliance rate with published
VTE prophylaxis guidelines is low. Decision on when to offer prophylaxis for hospitalized …

Background: Venous thromboembolism (VTE) prophylaxis remains underutilized,
particularly in cancer patients. We explored clinical predictors of prophylaxis in hospitalized …

Abstract Abstract 2503 Poster Board II-480 Because venous thromboembolism (VTE) often
occurs as a complication of cancer and chemotherapy, cancer patients have a 47-fold …

Abstract Abstract 674 Background: Paradigm changes in cancer therapy have shifted care to
primarily outpatient-based regimens. Venous thromboembolism (VTE) is a well-known …

Abstract Background The Khorana Score is a validated risk score for predicting 6‐month
incidence of cancer‐associated venous thromboembolism (CAT) among patients starting …

Venous thromboembolism (VTE) is a commonly encountered problem in patients with
cancer. In recent years, cancer treatment paradigm has shifted with most therapy offered in …

Background. Retrospective studies have suggested an association between cancer-
associated venous thromboembolism (VTE) and patient survival. We evaluated a previously …

Venous thromboembolism (VTE) is highly prevalent in patients with active malignancy,
although the risk varies widely [1, 2]. A majority of cancer-associated VTEs occur in the …